FDA acting director of cell and gene therapies Vijay Kumar to depart his post

Vijay Kumar, who has been serving as the acting director of the Center for Biologics Evaluation and Research (CBER) Office of Therapeutic Products, announced he will leave his position.

In an interview with Endpoints News, Kumar said he plans to explore career options both within the FDA and in the broader biotech sector.

The departure comes as the FDA continues to oversee an expanding portfolio of cell and gene therapy products, though no immediate impact on regulatory activities was indicated.

The agency has not named a successor, and Kumar’s exit is expected to be effective in the coming weeks.